已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison

阿替唑单抗 医学 彭布罗利珠单抗 贝伐单抗 肿瘤科 化疗 内科学 癌症 免疫疗法
作者
Balázs Halmos,Thomas Burke,Chrysostomos Kalyvas,Kristel Vandormael,Andrew M. Frederickson,Bilal Piperdi
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:155: 175-182 被引量:22
标识
DOI:10.1016/j.lungcan.2021.03.020
摘要

Multiple immunotherapy and chemotherapy combinations are approved for the management of advanced NSCLC which have not been directly compared in randomized clinical trials. This study indirectly compared the effectiveness of pembrolizumab + chemotherapy versus atezolizumab + chemotherapy+/-bevacizumab for previously untreated non-squamous NSCLC patients without EGFR/ALK aberrations.A matching-adjusted indirect comparison (MAIC) was conducted using individual patient data (IPD) from KEYNOTE-021 Cohort G (KN021 G) (pembrolizumab + carboplatin + pemetrexed; N = 59) and KEYNOTE-189 (KN189) (pembrolizumab + pemetrexed + platinum chemotherapy; N = 410) and published aggregate data from IMpower 130 (atezolizumab + carboplatin + nab-paclitaxel; N = 451) and IMpower 150 (atezolizumab + carboplatin + paclitaxel + bevacizumab; N = 356). To adjust for cross-trial differences in baseline characteristics, data from patients randomized to pembrolizumab + chemotherapy in KN021 G/KN189 were reweighted to match the baseline characteristics of patients randomized to atezolizumab + chemotherapy from IMpower 130 or atezolizumab + chemotherapy + bevacizumab from IMpower 150. Outcomes included overall survival (OS), blinded independent review-assessed progression-free survival (PFS) and objective response rate (ORR). OS and PFS follow-up were truncated to the trial with shorter follow-up. Sensitivity analyses were conducted without truncation of follow-up of OS and PFS.After matching for cross-trial differences, the effective sample size of pembrolizumab + chemotherapy was 428 and 389 for the IMpower 130 and IMpower 150 comparisons, respectively. The estimated HRs (95 % CIs) of pembrolizumab + chemotherapy versus atezolizumab + chemotherapy were 0.80 (0.67,0.95) and 0.79 (0.67,0.93) with regard to OS and PFS, respectively. For pembrolizumab + chemotherapy versus atezolizumab + chemotherapy + bevacizumab, the estimated HR (95 % CIs) was 0.86 (0.72,1.03) for OS and 0.81 (0.68,0.96) for PFS. For ORR, the estimated risk ratio (95 % CI) and the risk difference (95 % CI) was 0.9 (0.8,1.1) and -3.5 % (-10.0,3.1) for pembrolizumab + chemotherapy versus atezolizumab + chemotherapy, respectively, and 0.8 (0.7,0.9) and -12.2 % (-19.6,-4.8) for pembrolizumab + chemotherapy versus atezolizumab + chemotherapy + bevacizumab, respectively. Findings were consistent across sensitivity analyses for both outcomes.MAIC results showed a significantly better OS and PFS for pembrolizumab + chemotherapy compared with atezolizumab + chemotherapy and a significantly better PFS for pembrolizumab + chemotherapy compared with atezolizumab + chemotherapy + bevacizumab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er的应助被学术超女采纳,获得10
刚刚
sue发布了新的文献求助10
1秒前
2秒前
3秒前
传奇3的应助被没有好果汁吃采纳,获得10
3秒前
帅气恋风发布了新的文献求助10
4秒前
无奈甜瓜完成签到 ,获得积分10
4秒前
Owen的应助被707采纳,获得10
6秒前
我欣永恒发布了新的文献求助10
7秒前
哭泣的犀牛完成签到,获得积分20
8秒前
CipherSage的应助被狗头采纳,获得10
9秒前
风吹麦浪的应助被狗头采纳,获得10
9秒前
田様的应助被狗头采纳,获得10
9秒前
李健的小迷弟的应助被狗头采纳,获得10
9秒前
JamesPei的应助被狗头采纳,获得30
9秒前
默默的电话完成签到 ,获得积分10
10秒前
韦恩完成签到 ,获得积分10
11秒前
今天不跑WB完成签到 ,获得积分10
11秒前
13秒前
安静完成签到 ,获得积分10
16秒前
淡然夏寒发布了新的文献求助10
16秒前
王sohighs完成签到 ,获得积分10
17秒前
17秒前
17秒前
Bin完成签到,获得积分10
19秒前
小马甲的应助被dart1023采纳,获得10
19秒前
小明同学发布了新的文献求助10
19秒前
淡然之槐完成签到 ,获得积分10
20秒前
20秒前
小蘑菇的应助被帅气恋风采纳,获得10
21秒前
22秒前
Azhar发布了新的文献求助10
22秒前
artemis发布了新的文献求助10
24秒前
小二郎的应助被西瓜汁采纳,获得10
26秒前
颜林林发布了新的文献求助10
27秒前
28秒前
炙热梦曼发布了新的文献求助10
31秒前
CLAYmore发布了新的文献求助10
33秒前
科研通AI65的应助被小羊采纳,获得10
34秒前
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189808
求助须知:如何正确求助?哪些是违规求助? 9576988
关于积分的说明 21850976
捐赠科研通 7787775
什么是DOI,文献DOI怎么找? 3435793
关于科研通互助平台的介绍 2559844
邀请新用户注册赠送积分活动 2482687